LeMaitre Vascular(LMAT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Q4 2025 featured 16% sales growth, with a gross margin of 71.7% and operating income growth of 47% [4] - Q4 fully diluted earnings per share were $0.68, a 39% increase year-over-year [9] - For the full year 2025, organic revenue growth was 14%, with adjusted gross margin at 70.4% and adjusted EPS growth of 23% [10] Business Line Data and Key Metrics Changes - Sales growth in Q4 was led by grafts (up 27%), valvetomes (up 20%), and shunts (up 18%) [4] - RFA Vascular grew 19% and RFA Cardiac grew 90% in Q4 [4] - Autograft sales grew 29% worldwide in Q4, with international sales reaching $1.9 million in Q4 and $4 million for the full year 2025 [4] Market Data and Key Metrics Changes - EMEA region sales grew 29%, APAC grew 20%, and the Americas grew 10% in Q4 [4] - International sales of autograft are expected to reach approximately $10 million in 2026, contributing $6 million of sales growth for the year [4] Company Strategy and Development Direction - The company aims to produce quality devices, build its vascular sales force, go direct in new countries, acquire niche products, and focus on profitability, cash flow, and dividends [7] - The 2026 U.S. price list reflects a blended 8% increase across the portfolio, with early results indicating hospital acceptance [6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating revenue of $280 million, organic sales growth of 12%, and operating income of $77.8 million, up 21% adjusted from 2025 [12] - The company experienced a cyber incident in January 2026 but reported minimal disruption to sales and manufacturing [10][11] Other Important Information - The board approved a new $100 million share repurchase program and a Q1 2026 dividend of $0.25 per share, marking the 15th consecutive year of dividend increases [11] - The company ended 2025 with $359 million in cash and securities, with free cash flow of $74.5 million [10] Q&A Session Summary Question: Guidance and Operating Growth Factors - Management highlighted stable headcount, sales pricing growth, and manufacturing efficiencies as key factors for achieving operating growth above sales growth [15][16] Question: Price Increases and Future Outlook - Management noted that the smoother transition for price increases this year was due to earlier communication and preparation [18][19] Question: M&A Environment and Strategy - The company is actively pursuing M&A opportunities, focusing on open vascular and cardiac surgery markets, with 22 targets identified [30][32] Question: Artegraft Performance and Market Potential - Management revised the total addressable market (TAM) for Artegraft in Europe to $30 million, indicating stronger than expected performance [34][35] Question: Impact of CREST-2 Trial on Carotid Business - Management stated that the carotid shunt business remains resilient and is transitioning to an OUS business model [70][72] Question: Gross Margin Outlook - Management expects continued gross margin improvement, with guidance for a 170 basis point increase from 2025 to 2026 [80][82] Question: Restore Flow Manufacturing Transfer - The transfer of Restore Flow manufacturing is expected to be a slight headwind to margins in 2026, with costs already included in guidance [102]